Doctor profile · Federal record
Dr. MAEN ABDELRAHIM, MD
Medical Oncology Physician (CMS: MEDICAL ONCOLOGY) · Internal Medicine Physician · HOUSTON, TX
- NPI 1518227735
- Accepts Medicare
- 14 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
Operates at 2 locations .
- Primary practice
-
6445 MAIN STREET, OPC24
HOUSTON, TX 77030
(713) 441-9948 - Additional location
-
1709 Dryden Rd Ste 5.78, Faculty Center, BCM 620
Houston, TX 770302400
(713) 798-0190
Credentials & registration
- NPI registered
- May 2012 — 14 yrs on file
- Profile last updated
- March 17, 2018
- Year of graduation
- 2012 — 14 yrs since
- Specialty taxonomy
- 207RX0202X — NUCC code
- State licenses (2)
- Texas #Q1781 · Texas #BP10043067
- Medicaid
- TX #374923601
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1518227735. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
278
Distinct HCPCS
3
Medicare allowed
$49,482
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
99215 |
Established patient office or other outpatient visit, 40-54 minutes | 233 | 96 | $179 | |
99222 |
Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 23 | 14 | $127 | |
99205 |
New patient office or other outpatient visit, 60-74 minutes | 22 | 22 | $224 |
In context: peer comparison
Among 72 peers in this city , average services per provider: 632. This provider delivers 0.4× the peer median.Open Payments
Industry payments received
All-time total
$355,742
Transactions
204
Manufacturers
13
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 77 | $165,485.89 | |
| Ipsen Biopharmaceuticals, Inc | 44 | $84,738.54 | |
| Astellas Pharma US Inc | 23 | $34,217.54 | |
| AstraZeneca Pharmaceuticals LP | 24 | $31,853.71 | |
| PFIZER INC. | 9 | $17,938.77 | |
| ARRAY BIOPHARMA INC | 5 | $12,112.02 | |
| E.R. Squibb & Sons, L.L.C. | 10 | $3,064.13 | |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $2,220.00 | |
| Astellas Pharma Global Development | 1 | $2,187.50 | |
| Exelixis Inc. | 2 | $1,756.32 | |
| ABBVIE INC. | 5 | $88.18 | |
| Eisai Inc. | 2 | $55.98 | |
| Genentech USA, Inc. | 1 | $23.32 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
255
Patients
79
Total drug cost
$79,020
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Ondansetron Hcl | Generic | 39 | 22 | $1,381 |
| Prochlorperazine Maleate | Generic | 38 | 27 | $522 |
| Ondansetron Odt (Ondansetron) | Brand | 26 | 17 | $692 |
| Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen) | Brand | 22 | 13 | $580 |
| Eliquis (Apixaban) | Brand | 21 | 0 | $12,035 |
| Gabapentin | Generic | 20 | 0 | $187 |
| Potassium Chloride | Generic | 18 | 0 | $159 |
| Creon (Lipase/Protease/Amylase) | Brand | 17 | 0 | $43,800 |
| Dronabinol | Generic | 15 | 0 | $2,234 |
| Diphenoxylate-Atropine (Diphenoxylate Hcl/Atropine) | Brand | 14 | 0 | $256 |